Trevi Therapeutics' Upcoming Participation in Major Conferences
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER), is looking forward to participating in several notable conferences this September. These events serve as a platform for the company's senior management to present critical information regarding their work in treating chronic cough related to conditions such as idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Key Conferences to Attend This September
Wells Fargo Healthcare Conference
The 2025 Wells Fargo Healthcare Conference, scheduled for early September, will be a significant event for Trevi. It will feature participation from Jennifer Good, President and CEO, alongside Farrell Simon, Pharm.D., Chief Commercial Officer. The conference will take place from September 3 to September 5.
Cantor Global Healthcare Conference
Shortly after, Trevi's team will also be present at the Cantor Global Healthcare Conference, which runs parallel with the Wells Fargo conference, from September 3 to September 5. Jennifer Good will share insights alongside James Cassella, Ph.D., Chief Development Officer.
Morgan Stanley Healthcare Conference
The Morgan Stanley 23rd Annual Global Healthcare Conference will occur from September 8 to September 10. Trevi will host a fireside chat on September 9 at 4:05 p.m. ET, where Jennifer Good and James Cassella will discuss advancements in their research and the potential of Haduvio in treating chronic cough.
H.C. Wainwright & Co. Investment Conference
Following the Morgan Stanley conference, Trevi will participate in the H.C. Wainwright & Co. 27th Annual Global Investment Conference, also from September 8 to September 10. Here, the company will again feature Jennifer Good and Farrell Simon to highlight the potential impact of their treatment innovations.
Understanding the Impact of Haduvio
Haduvio is at the forefront of Trevi's research. It aims to target chronic cough effectively, specifically in patients suffering from conditions such as IPF, which affects a significant portion of the population with up to 85% experiencing chronic cough. In the U.S. alone, the number of individuals diagnosed with IPF is approximately 150,000.
Challenges of Chronic Cough in IPF Patients
Chronic cough presents profound challenges, including frequent episodes of coughing that can reach up to 1,500 times per day, heavily impacting daily life and leading to worsened health outcomes. Unfortunately, there are currently no approved therapies addressing this critical need effectively.
Tackling Refractory Chronic Cough
Another area where Trevi Therapeutics aims to make a difference is in refractory chronic cough, defined as a cough persisting more than eight weeks despite treatment of underlying conditions. This affects millions in the U.S., and there are no approved medications available. Haduvio seeks to address underlying issues related to cough reflex hypersensitivity, providing a much-needed option.
The Future of Cough Therapy
As Trevi Therapeutics steps into these conferences, they not only represent their current research but also demonstrate their commitment to bringing innovative therapies to market. By positioning Haduvio as the first investigational therapy to significantly reduce cough frequency, Trevi is paving the way for advancements in treatment protocols for chronic cough.
Company Overview
Founded with the mission to innovate healthcare, Trevi Therapeutics focuses on developing therapies like Haduvio to help patients suffering from chronic cough due to serious lung diseases. Haduvio acts on the cough reflex through a unique mechanism, supporting Trevi's dedication to improving the quality of life for affected individuals.
Frequently Asked Questions
What is Trevi Therapeutics known for?
Trevi Therapeutics is primarily known for developing Haduvio, a therapy aimed at treating chronic cough in patients with conditions like IPF and RCC.
What conferences is Trevi participating in September?
Trevi will participate in major healthcare conferences, including the Wells Fargo, Cantor Global, Morgan Stanley, H.C. Wainwright, and the Leerink Partners Biopharma Summit.
What is chronic cough and why is it a concern?
Chronic cough is a sustained cough lasting more than eight weeks, significantly affecting the quality of life and often linked to serious lung diseases like IPF.
How does Haduvio work?
Haduvio works by targeting the cough reflex both centrally and peripherally, acting as a kappa agonist and a mu antagonist to reduce cough frequency.
Can Haduvio be used for refractory chronic cough?
Yes, Haduvio is being developed specifically to address refractory chronic cough, providing hope for those who have found no relief from existing treatments.
